SEC Form 10-Q Summary
Registrant and period: The filing is for Pono Capital Two, Inc., a Delaware special purpose acquisition company (SPAC), for the three months ended March 31, 2024, filed May 20, 2024. Although the request identifies SBC Medical Group Holdings Inc., the supplied filing is issued by Pono Capital Two and describes its proposed combination with SBC.
Business Context and Reporting Period
Pono Capital Two was formed to complete a business combination and had not commenced operating activities as of March 31, 2024. It has generated no operating revenue; activity primarily relates to its initial public offering, trust-account investments, public-company expenses, and pursuit of the proposed merger with SBC Medical Group Holdings Incorporated.
The proposed transaction would merge Pono’s wholly owned subsidiary with SBC, with SBC surviving. SBC is expected to restructure so that SBC Medical Group Co., Ltd. and related entities become subsidiaries of SBC. The merger agreement was amended in April 2024 to extend the outside date to September 30, 2024. Pono’s business-combination deadline was extended to November 9, 2024.
Financial Metrics
| Metric | Three months ended March 31, 2024 | Three months ended March 31, 2023 |
|---|---|---|
| Operating and formation costs | $462,639 | $374,488 |
| Franchise tax expense | $42,027 | $13,959 |
| Loss from operations | $(504,666) | $(388,447) |
| Trust-account interest and dividend income | $257,335 | $1,264,475 |
| Income tax expense | $45,215 | $262,695 |
| Net income (loss) | $(292,546) | $613,333 |
| Basic and diluted loss per share | $(0.05) | Basic and diluted income per share: $0.04 |
| Net cash used in operating activities | $(487,452) | $(393,819) |
As of March 31, 2024, cash outside the trust account was $1.66 million, marketable securities held in the trust account were $17.98 million, total assets were $19.75 million, and total liabilities were $8.43 million. Current liabilities included a $2.70 million convertible promissory note, $1.03 million of excise tax payable, and $0.51 million of accrued expenses. Deferred underwriting fees were $4.03 million.
Stockholders’ equity was $9.02 million, compared with a deficit of $5.99 million at December 31, 2023, primarily reflecting the reclassification of 1,435,811 Class A shares purchased by a holder who forfeited redemption rights. Class A shares subject to possible redemption totaled 213,605 shares with a redemption value of $2.31 million.
Net cash provided by investing activities was $3.13 million, including $2.96 million withdrawn from the trust account for redemptions and $162,809 withdrawn to pay taxes. Financing activities used $1.26 million, consisting of $2.96 million paid to redeeming stockholders, partially offset by $1.70 million of proceeds from the amended convertible promissory note.
Material Changes Versus the Prior Comparable Period
- The company moved from net income of $613,333 to a net loss of $292,546.
- Trust-account interest income declined by approximately $1.01 million, while operating and formation costs increased by approximately $88,000.
- Operating cash use increased by approximately $94,000.
- The trust account declined from $20.85 million at December 31, 2023 to $17.98 million at March 31, 2024, reflecting redemptions and tax payments.
- The convertible promissory note increased from $1.00 million to $2.70 million. It is non-interest-bearing, automatically convertible into Class A common stock at one share per $10 of principal, and matures upon the earlier of the business-combination closing or August 29, 2024.
- On February 5, 2024, stockholders approved an extension of the business-combination deadline to November 9, 2024 and redeemed 273,334 Class A shares for $2.96 million.
- The merger consideration formula was previously reduced from $1.20 billion to $1.00 billion, subject to adjustments for working capital, debt, cash, and transaction expenses.
Guidance, Outlook, Risks, and Unusual Items
Management expects to complete the business combination before November 9, 2024 but provides no assurance that it will do so. If the transaction is not completed by that date, the company must cease operations, redeem public shares using the trust account, and liquidate. Management states that the deadline and limited liquidity create substantial doubt about the company’s ability to continue as a going concern.
The company expects additional capital may be required to fund working capital needs and consummate the business combination. Potential working-capital loans of up to $1.50 million have been discussed, but there is no guarantee that such funding will be provided.
The company recorded an excise-tax liability of $1.03 million related to stock redemptions under the Inflation Reduction Act. The ultimate effect of the excise tax could reduce funds available for the business combination.
After the reporting date, Nasdaq notified the company that it did not satisfy requirements relating to publicly held shares, minimum market value of publicly held shares, and total holders. The notices had no immediate effect on trading. The company submitted compliance plans on May 16, 2024; failure to regain compliance could result in delisting.
The filing reports no material litigation and no off-balance-sheet arrangements. Management concluded that disclosure controls and procedures were effective as of March 31, 2024, with no material changes in internal control over financial reporting during the quarter.
Important Facts for Investors to Verify
- Confirm the correct issuer: the supplied 10-Q is for Pono Capital Two, Inc., not an operating-company 10-Q filed directly by SBC Medical Group Holdings Inc.
- Track whether the proposed SBC transaction closes by the September 30, 2024 merger outside date and the November 9, 2024 SPAC liquidation deadline.
- Review the final merger consideration, including adjustments for SBC working capital, debt, cash, and transaction expenses.
- Assess available trust-account funds after redemptions, taxes, deferred underwriting fees, and any further redemptions.
- Evaluate the $2.70 million convertible note, potential dilution, and any additional working-capital financing.
- Monitor Nasdaq compliance plans and the risk of delisting.
- Verify the effect and ultimate amount of the Inflation Reduction Act excise-tax liability.
- Review the merger proxy and subsequent SEC filings for transaction approvals, remaining SEC comments, redemption terms, and closing conditions.